Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer’

被引：0
|
作者：
K-L G Spindler
N Pallisgaard
R F Andersen
A Jakobsen
机构：
[1] Vejle Hospital,Department of Oncology
[2] Danish Colorectal Cancer Group South,Department of Biochemistry
[3] Vejle Hospital,undefined
[4] Kabbeltoft 25,undefined
[5] Vejle Hospital,undefined
[6] Current address: Department of Oncology,undefined
[7] Aarhus University Hospital,undefined
[8] Aarhus,undefined
[9] Denmark,undefined
来源：
British Journal of Cancer | 2014年 / 111卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2380 / 2380
相关论文
共 50 条
  • [1] Response to comment on 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
    Spindler, K-L G.
    Pallisgaard, N.
    Andersen, R. F.
    Jakobsen, A.
    BRITISH JOURNAL OF CANCER, 2014, 111 (12) : 2380 - 2380
  • [2] Comment on 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
    Tougeron, D.
    Laurent-Puig, P.
    Zaanan, A.
    BRITISH JOURNAL OF CANCER, 2014, 111 (12) : 2379 - 2380
  • [3] Comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer’
    D Tougeron
    P Laurent-Puig
    A Zaanan
    British Journal of Cancer, 2014, 111 : 2379 - 2380
  • [4] KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
    Spindler, K. G.
    Appelt, A. L.
    Pallisgaard, N.
    Andersen, R. F.
    Jakobsen, A.
    BRITISH JOURNAL OF CANCER, 2013, 109 (12) : 3067 - 3072
  • [5] KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
    K G Spindler
    A L Appelt
    N Pallisgaard
    R F Andersen
    A Jakobsen
    British Journal of Cancer, 2013, 109 : 3067 - 3072
  • [6] KRAS mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
    Spindler, K.
    Appelt, A. L.
    Pallisgaard, N.
    Andersen, R. F.
    Jakobsen, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S11 - S11
  • [7] Microenvironment targets in KRAS-mutated metastatic colorectal cancer
    Marchio, Serena
    Bartolini, Alice
    Cardaci, Sabrina
    Soster, Marco
    Corti, Giorgio
    Lamba, Simona
    Bussolino, Federico
    Cora', Davide
    Nicolantonio, Federica D.
    CANCER RESEARCH, 2014, 74 (19)
  • [8] Advanced therapies on BRAF-mutated and KRAS-mutated metastatic colorectal cancer
    LI Zi-nan
    YU Li-feng
    WANG Jia-qi
    NIU Yan-xin
    WANG Xin-yu
    ZHAO Lin
    中国药理学与毒理学杂志, 2019, (10) : 883 - 883
  • [9] Early changes in circulating tumor DNA (ctDNA) predict treatment response in metastatic KRAS-mutated colorectal cancer (mCRC) patients
    Lavacchi, Daniele
    Gelmini, Stefania
    Calabri, Adele
    Rossi, Gemma
    Simi, Lisa
    Caliman, Enrico
    Mancini, Irene
    Salvianti, Francesca
    Petroni, Giulia
    Guidolin, Alessia
    Scolari, Federico
    Messerini, Luca
    Pillozzi, Serena
    Pinzani, Pamela
    Antonuzzo, Lorenzo
    HELIYON, 2023, 9 (11)
  • [10] Polo-like Kinase 1 Inhibition in KRAS-Mutated Metastatic Colorectal Cancer
    Stebbing, Justin
    Bullock, Andrea J.
    CLINICAL CANCER RESEARCH, 2024, 30 (10) : 2005 - 2007
12345